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EGFR copy number per se can affect the clinical outcome of adenocar-
cinoma of the lung after surgical resection.
Methods: We analyzed 106 cases of primary pulmonary adenocarcino-
ma who underwent curative resection and whose parafﬁn blocks were 
available. We excluded patients who received preoperative chemother-
apy and who were presented with distant metastasis. The EGFR gene 
copy number was evaluated using ﬂuorescence in situ hybridization 
(FISH) and its prognostic implication was analyzed along with other 
clinical risk factors. 
Results: There were 43 males and 63 females and the mean age was 
59.4 (29-85) years. We detected a high EGFR gene copy number in 39 
cases (36.8%), among whom, 8 cases (7.5%) showed ampliﬁcation. 
The high EGFR gene copy was not associated with gender, smoking 
status, presence of bronchioloalveolar cell feature, or pathologic TNM 
stage. All patients were followed up at the clinic with mean follow 
up periods of 27.7 (2.9-69.6) months. The overall 5 year survival was 
54.6% and that of disease speciﬁc survival was 38.2%. The risk factors 
affecting the overall survival were male gender (p=0.0007), smoking 
history (p=0.0093), and advanced stage (≥IIA; p=0.0375) in univari-
able analysis. For disease speciﬁc survival, male gender (p=0.0333), 
absence of bronchioloalveolar feature (p=0.0223), advanced stage 
(p=0.0016), and ampliﬁcation of EGFR gene copy (p=0.0295) were 
risk factors in univariable analysis. In multivariable analysis, advanced 
stage (p=0.001) and EGFR gene ampliﬁcation (p=0.014) remained as 
signiﬁcant risk factors for poor disease speciﬁc survival.
Conclusions: We demonstrated that ampliﬁcation of the EGFR gene 
affected the clinical outcome of adenocarcinoma of the lung after surgi-
cal resection in terms of disease speciﬁc survival. This result provides 
an important message for the protocol design of future trials using 
EGFR inhibitor. As EGFR gene ampliﬁcation itself is a poor prognostic 
factor for disease recurrence, the EGFR gene copy number should be 
investigated and analyzed in the context of other clinical risk factors in 
such clinical trials. 
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Background: We evaluated the correspondence between EGFR 
mutations in NSCLC tissue and matched serum DNA and the value of 
EGFR mutations as a serological marker. 
Methods: 121 Spanish stage IV NSCLC p received customized ﬁrst- or 
second-line erlotinib monotherapy based on the presence of EGFR 
mutations in the tumor tissue. Serum genomic DNA was obtained from 
all p prior to erlotinib administration. EGFR exon 19 deletions were 
studied by length analysis of ﬂuorescently labeled PCR products and 
the exon 21 L858R mutation by a PCR Taqman assay. 
Results: The EGFR mutation status in the serum was consistent with 
that in the tumor tissue of 82/121 p (68%) and of 15/16 p (93.8%) with 
PS 2 had mutations. Overall, 64.3% of p had an exon 19 deletion and 
35.7% had L858R. 78% of mutations were found in females (P=0.01) 
and 77.6% in never-smokers (P=0.07). Response rate was 88% in 
p with mutations only in the tumor and 87% in p with mutations in 
tumor and serum. Complete responses were observed in 20% of p with 
mutations in tumor and serum vs 4% of p with mutations only in tumor 
(P=0.09). With a median follow-up of 6.8 months (m) (range, 1.2-17.6), 
time to progression (TTP) and median survival have not been reached. 
A trend to better outcome was seen in p without serum EGFR muta-
tions. TTP was longer for p with EGFR exon 19 deletions (not reached) 
than for p with L858R (7.7 m) (P=0.02). TTP for p with PS 2 with exon 
19 deletions was not reached, while it was 2.7 m for p with L858R 
(P=0.17). 
Conclusions: EGFR mutations in serum could be a non-invasive 
source of information on the genotype of the original tumor cells and 
could be a useful tool to predict p response to erlotinib, especially in p 
with poor PS.
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